This company has been acquired
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
DICE Therapeutics 과거 수익 실적
과거 기준 확인 0/6
DICE Therapeutics's earnings have been declining at an average annual rate of -51%, while the Pharmaceuticals industry saw earnings growing at 16% annually.
주요 정보
-51.0%
수익 성장률
48.6%
EPS 성장률
| Pharmaceuticals 산업 성장 | 6.0% |
| 매출 성장률 | n/a |
| 자기자본 수익률 | -20.1% |
| 순이익 | n/a |
| 최근 수익 업데이트 | 30 Jun 2023 |
최근 과거 실적 업데이트
Recent updates
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate
May 14
DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher
Oct 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11DICE Therapeutics GAAP EPS of -$0.58
Aug 11DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs
Jul 18수익 및 비용 분석
DICE Therapeutics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -104 | 32 | 24 |
| 31 Mar 23 | 0 | -91 | 28 | 0 |
| 31 Dec 22 | 0 | -84 | 26 | 0 |
| 30 Sep 22 | 0 | -77 | 23 | 0 |
| 30 Jun 22 | 0 | -74 | 21 | 0 |
| 31 Mar 22 | 1 | -59 | 16 | 0 |
| 31 Dec 21 | 1 | -49 | 12 | 0 |
| 30 Sep 21 | 1 | -40 | 9 | 0 |
| 30 Jun 21 | 2 | -29 | 7 | 0 |
| 31 Mar 21 | 1 | -27 | 5 | 0 |
| 31 Dec 20 | 1 | -24 | 5 | 0 |
| 31 Dec 19 | 6 | -13 | 4 | 0 |
양질의 수익: DICE is currently unprofitable.
이익 마진 증가: DICE is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: DICE is unprofitable, and losses have increased over the past 5 years at a rate of 51% per year.
성장 가속화: Unable to compare DICE's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: DICE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-16.4%).
자기자본 수익률
높은 ROE: DICE has a negative Return on Equity (-20.08%), as it is currently unprofitable.